RE:RE:RE:Second Mysterious Formulation of Avenanthramide:I can forgive GG for the trials but not developing a competent management team speaks volumes. He's being paid handsomely along with the stock options all these years yet has only hired a CRO this past year after much pressure from us shareholders.
As for proph, thanks for sharing your research findings - if only you worked for CZO (or maybe you already do). It just shows how much we're lacking in planning and execution - if avenanthramides was the end goal, why waste all those time and resources on a poorly executed BG pill study that we later find out a powder could be more efficient? Yes, pill has significant advantages with the form factor but it's ineffective, doesn't matter if it's a pill or not eh?
As for the news release Proph shared, here's another one from October 2018 (five years ago) - notice the same language and promise - "significant transformational step taken to date.."
(BG Pill study). You can even replace Beta Glucan with Avenanthramides. “The commencement of this study represents a noteworthy milestone in the development of our [beta glucan program] and could be the most significant transformational step we have taken to date in executing on our strategy to transition Ceapro’s business model towards becoming a biopharmaceutical company with the potential to provide an innovative product in a multi-billion dollar and growing market. On the technical side, we are pleased with the final formulation of [beta glucan powder], which has been produced in house using our disruptive PGX technology and additionally with the final tablet developed with Montreal-based specialty pharmaceutical companies, Corealis and Halo Pharma, who respectively completed the pharmaceutical development and the production of clinical lots for the trial. We are extremely grateful to be working with the expert team led by Dr. Tardif at MHI and MHICC, who shares a synergistic goal in Ceapro’s contemplated sector of activities in inflammation-based diseases, metabolic syndrome and other lifestyle diseases,” added Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.